Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to advancing therapies for genetically defined diseases with significant unmet medical needs. With a robust pipeline centered on addressing conditions such as Duchenne Muscular Dystrophy, Fulcrum aims to transform patient care through innovative drug development. The company's commitment to leveraging its proprietary drug discovery platform underscores its strategic focus on precision medicine and its potential to deliver meaningful clinical benefits.